Blog: IsoPlexis Data Network

Industry pioneers' backed data straight to your inbox.

Checkpoint Therapy Development and Biomarkers: Why Single-Cell Proteomics Is a Powerful Source of Insight

Next Generation Quality and Potency Metric for Allogeneic CAR-T Cell Products

Next Generation Preclinical Advancement of CAR-T Therapy: Improved Function and Efficacy in Multiple Myeloma

CAR-T Leader Makes Strides in the Bispecifics Space: See What’s Next for Functional Single-Cell Proteomics

Value of Cellular Proteomics: Confirming Critical Cellular Immune Function After Making Complex Gene Edits in Solid Tumor Therapies

Value of Cellular Proteomics: Completing the Functional Puzzle

Why Difficult Combination Checkpoint Pre-Clinical Development Choice is Evolving with IsoPlexis’ Single-Cell Cytokine Analysis

Getting the Most Out of Your CAR-T Bioprocessing with the CliniMACS Prodigy® & IsoCode Single-Cell Chip

IsoPlexis, Kite Pharma, Takeda, and Legend Biotech Presented Panel at 2019 CAR-TCR Summit

Checkpoint Immunotherapy in Solid Tumor Is Evolving: Advancing Cellular Fitness & Precision Medicine with IsoPlexis’ Platform